PLYMOUTH MEETING, Pa. and WESTFORD, Mass., Feb. 1 /PRNewswire/ -- BioBehavioral Diagnostics (BioBDx), a privately held company which manufactures and markets the Quotient(TM) ADHD System, a tool that aids in the objective and accurate assessment of attention-deficit hyperactivity disorder (ADHD), announced today the first close of a $10 million Series B financing. Sevin Rosen and Tullis Dickerson led the round.
“Nearly 10 million children, adolescents and adults have been diagnosed with ADHD in the U.S, yet there remains a huge unmet need for more accurate and objective clinical tools,” remarked CEO Byron Hewett. “The Quotient ADHD System provides clinicians with objective analysis of the key symptoms of ADHD that results in better, less costly clinical care.” Hewett concluded, “We are excited to be on the cutting edge of this important advance in the assessment of ADHD and ultimately contributing to making a difference in people’s lives.”
About the Quotient(TM) ADHD System
The Quotient(TM) ADHD System collects and reports objective, accurate data on hyperactivity, impulsivity and inattention. The clinician integrates the Quotient(TM) ADHD Test report with information from other assessment tools and the clinical evaluation to guide treatment decisions. For more information about the Quotient(TM) ADHD System, please visit http://www.biobdx.com/Products/QuotientADHDSystem.aspx.
For more information about BioBehavioral Diagnostics, please visit www.BioBDx.com.
BioBehavioral Diagnostics Company
